Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04576091
Title Testing the Addition of an Anti-cancer Drug, BAY1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

hypopharynx cancer

oropharynx cancer

laryngeal squamous cell carcinoma

oral squamous cell carcinoma

head and neck squamous cell carcinoma

Therapies

BAY1895344 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Los Angeles County-USC Medical Center Recruiting Los Angeles California 90033 United States Details
USC / Norris Comprehensive Cancer Center Recruiting Los Angeles California 90033 United States Details
University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor Michigan 48109 United States Details
Duke University Medical Center Recruiting Durham North Carolina 27710 United States Details
University of Oklahoma Health Sciences Center Recruiting Oklahoma City Oklahoma 73104 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field